Vidula, Neelima http://orcid.org/0000-0002-5963-7052
Niemierko, Andrzej
Hesler, Katherine
Ryan, Lianne
Moy, Beverly http://orcid.org/0000-0003-3472-1140
Isakoff, Steven http://orcid.org/0000-0002-6677-1014
Ellisen, Leif http://orcid.org/0000-0003-0444-7910
Juric, Dejan http://orcid.org/0000-0003-2983-7704
Bardia, Aditya
Article History
Received: 27 June 2022
Accepted: 30 March 2023
First Online: 19 April 2023
Competing interests
: No funding was provided for this study. Individual disclosures for co-authors are as noted below: A.N.: The author declares no competing financial and non-financial interests. K.S.: The author declares no competing financial and non-financial interests. L.R.: The author declares no competing financial and non-financial interests. B.M.: The author declares no competing financial and non-financial interests. S.I.: The author declares no competing financial and non-financial interests. L.E.: The author declares no competing financial and non-financial interests. N.V.: The author declares no competing non-financial interests but the following competing financial interests: Research funding (for clinical trials not related to this work) to the institution (Massachusetts General Hospital): Merck, Daehwa, Pfizer, Radius, and Novartis; Advisory board participation (single session, not related to this work): AbbVie, OncoSec, TerSera, and Gilead DJ: The author declares no competing non-financial interests but the following competing financial interests: Consulting fees from Novartis, Genentech, Syros, Eisai, Vibliome, Mapkure, and Relay Therapeutics. Contracted research with Novartis, Genentech, Syros, Pfizer, Eisai, Takeda, Ribon Therapeutics, Infinity, InventisBio, Cyteir, Blueprint Medicines and Arvinas. Ownership interest in Relay Therapeutics and PIC Therapeutics. A.B.: The author declares no competing non-financial interests but the following competing financial interests: Consultant/Advisory board: Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics/Gilead, Sanofi, Daiichi Pharma/Astra Zeneca, Phillips, Eli Lilly, Foundation Medicine. Contracted Research/Grant (to institution): Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Pharma/Astra Zeneca, Eli Lilly.